Enrica Marchi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Enrica Marchi has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Ayman Mithqal
Division of Body Imaging, Department of Radiology and Medical Imaging, University of Virginia, Charlottesville, VA
1 shared publication - Bethany Jablonski Horton
Division of Translational Research & Applied Statistics, Department of Public Health Sciences, University of Virginia, Charlottesville, VA 22908, USA
1 shared publication - Elizabeth Courville
Division of Anatomic Pathology, Department of Pathology, University of Virginia, Charlottesville, VA
1 shared publication - Gautham Prakash
Division of Hematology and Oncology, Department of Medicine, University of Virginia, Charlottesville, VA
1 shared publication - Gina R. Petroni
Division of Translational Research & Applied Statistics, Department of Public Health Sciences, University of Virginia, Charlottesville, VA 22908, USA
1 shared publication - Himesh B. Zaver
Division of Gastroenterology and Hepatology, University of Virginia Health System, Charlottesville, VA
1 shared publication
Latest Publications
- Open Access
Design of a Phase I Drug Combination Study with Adaptive Allocation Based on Dose-Limiting Toxicity Attribution
Background: This article describes the adaptation of a Phase I drug combination method to incorporate dose-limiting toxicity (DLT) attribution in dose assignments. The study is motivated by the Embolden trial (NCT03240211), a Phase Ib, multicenter trial at the UVA Comprehensive Cancer Center evaluating pembrolizumab with pralatrexate (Arm A), decitabine (Arm C), or both (Arm B) in relapsed/refractory peripheral and cutaneous T cell lymphomas. Methods: While Arms A and C used monotherapy dose escalation, Arm B required simultaneous escalation of both agents, integrating drug-specific DLT attribution to guide dosing. Results: We adapted the partial order continual reassessment method (POCRM) to incorporate this attribution, ensuring appropriate de-escalation of the offending agent. Given the trial’s complexity, software modifications were necessary to evaluate design performance through simulations. Conclusions: This work underscores the importance of novel dose-finding strategies in early-phase trials and aims to promote their broader adoption for improved trial efficiency and transparency.
Open AccessDesign of a Phase I Drug Combination Study with Adaptive Allocation Based on Dose-Limiting Toxicity Attribution
Background: This article describes the adaptation of a Phase I drug combination method to incorporate dose-limiting toxicity (DLT) attribution in dose assignments. The study is motivated by the Embolden trial (NCT03240211), a Phase Ib, multicenter trial at the UVA Comprehensive Cancer Center evaluating pembrolizumab with pralatrexate (Arm A), decitabine (Arm C), or both (Arm B) in relapsed/refractory peripheral and cutaneous T cell lymphomas. Methods: While Arms A and C used monotherapy dose escalation, Arm B required simultaneous escalation of both agents, integrating drug-specific DLT attribution to guide dosing. Results: We adapted the partial order continual reassessment method (POCRM) to incorporate this attribution, ensuring appropriate de-escalation of the offending agent. Given the trial’s complexity, software modifications were necessary to evaluate design performance through simulations. Conclusions: This work underscores the importance of novel dose-finding strategies in early-phase trials and aims to promote their broader adoption for improved trial efficiency and transparency.
- Open Access
- 1 February 2025
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 12 (2) , e01618
A Post-transplant Immunosuppression Complication: Epstein-Barr Virus-Positive Classic Hodgkin Lymphoma Post-transplant Lymphoproliferative Disorder
Post-transplant lymphoproliferative disorder (PTLD) is a potential life-threatening complication after solid organ transplantation. PTLD can be associated with Epstein-Barr virus through either primary infection or reactivation during treatment with immunosuppressive medications. We present a rare case of Epstein-Barr virus-positive classical Hodgkin lymphoma PTLD following liver transplantation, which was initially misattributed to late transplant rejection and raised concerns for cholangiocarcinoma due to abnormal laboratory and imaging findings.
- 1 February 2025
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 12 (2) , e01618
Open AccessA Post-transplant Immunosuppression Complication: Epstein-Barr Virus-Positive Classic Hodgkin Lymphoma Post-transplant Lymphoproliferative Disorder
Post-transplant lymphoproliferative disorder (PTLD) is a potential life-threatening complication after solid organ transplantation. PTLD can be associated with Epstein-Barr virus through either primary infection or reactivation during treatment with immunosuppressive medications. We present a rare case of Epstein-Barr virus-positive classical Hodgkin lymphoma PTLD following liver transplantation, which was initially misattributed to late transplant rejection and raised concerns for cholangiocarcinoma due to abnormal laboratory and imaging findings.
- 31 October 2024
- Published by American Society of Hematology in Blood
- Vol. 144 (18) , 1898-1909
Current and upcoming treatment approaches to uncommon subtypes of PTCL (EATL, MEITL, SPTCL, and HSTCL)
Rare subtypes of peripheral T-cell lymphoma (PTCL) including enteropathy-associated T-cell lymphoma (EATL), monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL), subcutaneous panniculitis–like T-cell lymphoma (SPTCL), and hepatosplenic T-cell lymphoma (HSTCL) are underrepresented in most registries and clinical studies. Most of the literature is obtained from small case series, single-institution retrospective studies, and subgroup analyses of the largest studies with few recent and ongoing exceptions. Although the pathogenesis and biology of these entities have yet to be fully elucidated, global efforts by the scientific community have started to shed some light on the most frequently deregulated pathways. In this review, we highlight the most pertinent clinical and pathologic features of rare subtypes of PTCL including EATL/MEITL, SPTCL, and HSTCL. We also summarize the results of recent developments identifying potential targets for novel therapeutic strategies based on molecular studies. Finally, we highlight the underrepresentation of these rare subtypes in most clinical trials, making evidence–based therapeutic decisions extremely challenging.
- 31 October 2024
- Published by American Society of Hematology in Blood
- Vol. 144 (18) , 1898-1909
Current and upcoming treatment approaches to uncommon subtypes of PTCL (EATL, MEITL, SPTCL, and HSTCL)
Rare subtypes of peripheral T-cell lymphoma (PTCL) including enteropathy-associated T-cell lymphoma (EATL), monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL), subcutaneous panniculitis–like T-cell lymphoma (SPTCL), and hepatosplenic T-cell lymphoma (HSTCL) are underrepresented in most registries and clinical studies. Most of the literature is obtained from small case series, single-institution retrospective studies, and subgroup analyses of the largest studies with few recent and ongoing exceptions. Although the pathogenesis and biology of these entities have yet to be fully elucidated, global efforts by the scientific community have started to shed some light on the most frequently deregulated pathways. In this review, we highlight the most pertinent clinical and pathologic features of rare subtypes of PTCL including EATL/MEITL, SPTCL, and HSTCL. We also summarize the results of recent developments identifying potential targets for novel therapeutic strategies based on molecular studies. Finally, we highlight the underrepresentation of these rare subtypes in most clinical trials, making evidence–based therapeutic decisions extremely challenging.